Stock-Based Compensation | 5. Stock-Based Compensation The compensation costs that have been charged against income for the thirteen weeks ended May 5, 2018 and April 29, 2017 were as follows (in thousands): Thirteen Weeks Ended May 5, 2018 April 29, 2017 Stock-based compensation expense by type: Stock options $ 160 $ 173 Restricted stock unit awards, including performance-based 1,524 1,491 Employee stock purchases 29 33 Director deferred compensation 23 6 Total stock-based compensation expense 1,736 1,703 Income tax benefit recognized 393 614 Stock-based compensation expense, net of income tax $ 1,343 $ 1,089 In the thirteen weeks ended May 5, 2018 and April 29, 2017, we granted the following equity awards: Thirteen Weeks Ended May 5, 2018 April 29, 2017 Stock options 19,994 20,372 Restricted stock unit awards 169,572 108,429 Performance-based restricted stock unit awards 44,700 54,900 Deferred stock units 979 201 At May 5, 2018, the total compensation costs related to nonvested restricted stock unit awards not yet recognized was $8.5 million and the weighted-average period over which such awards are expected to be recognized was 3.2 years. The total compensation costs related to nonvested stock options to be recognized was $25,000 and the period over which the award is expected to be recognized was 0.4 years at May 5, 2018. Under the 2012 Non-Employee Director Equity Plan (2012 Plan), a total of 4,435 and 3,361 shares of our common stock were awarded during the thirteen weeks ended May 5, 2018 and April 29, 2017, respectively, as part of the annual equity award to directors in the first quarter. The weighted-average grant date fair value of stock options granted during the thirteen weeks ended May 5, 2018 and April 29, 2017 was $7.15 and $8.47 per share, respectively. Our employee purchases of common stock, the average price per share and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows: Thirteen Weeks Ended May 5, 2018 April 29, 2017 Shares purchased 6,554 5,464 Average price per share $ 17.34 $ 25.08 Weighted average fair value at grant date $ 4.53 $ 5.60 |